Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis.

Brian D. Juran, Elizabeth J. Atkinson, Erik M. Schlicht, Joseph J. Larson, David Ellinghaus, Andre Franke, Konstantinos N. Lazaridis

Research output: Contribution to journalArticle

Abstract

The damaging cholestasis inherent to primary sclerosing cholangitis (PSC) results from bile duct stricturing because of progressive fibrosis. The matrix metalloproteinase 3 (MMP3) degrades a wide range of matrix components and is expressed by activated liver stellate cells, and so is a candidate for involvement with the fibrotic processes underlying PSC. Moreover, the MMP3 gene harbours polymorphisms associated with variation in its activity directly impacting clinical phenotypes. We aimed to examine the influence of MMP3 polymorphisms on PSC risk and progression. Nine single nucleotide polymorphisms (SNPs) tagging the common genetic variation of MMP3 were genotyped in 266 PSC patients and 407 controls. SNPs and inferred haplotypes were assessed for PSC association by logistic regression and score tests. The effect of SNPs on survival to liver transplant or death was analysed using Cox regression, and Kaplan-Meier curves were constructed. No association of PSC with individual SNPs or haplotypes of MMP3 was detected. However, progression to death or liver transplant was significantly associated with homozygosity for minor alleles of rs522616, rs650108 and rs683878, particularly among PSC patients with concurrent ulcerative colitis (UC) (strongest in redundant SNPs rs650108/rs683878, hazard ratio=3.23, 95% confidence interval 1.45-7.25, P=0.004). Genetic variation in MMP3 influences PSC progression, possibly in the context of coexisting UC. While the functional variants and specific mechanisms remain unknown, this finding implicates the turnover of the extracellular matrix as an important and variable component of PSC pathogenesis. Efforts to understand this process could form the basis for developing effective treatments, which are currently lacking for PSC.

Original languageEnglish (US)
Pages (from-to)785-791
Number of pages7
JournalLiver international : official journal of the International Association for the Study of the Liver
Volume31
Issue number6
StatePublished - Jul 2011
Externally publishedYes

Fingerprint

Matrix Metalloproteinase 3
Sclerosing Cholangitis
Genetic Polymorphisms
Single Nucleotide Polymorphism
Ulcerative Colitis
Haplotypes
Liver
Transplants
Cholestasis
Bile Ducts
Extracellular Matrix
Fibrosis
Logistic Models
Alleles
Confidence Intervals
Phenotype

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. / Juran, Brian D.; Atkinson, Elizabeth J.; Schlicht, Erik M.; Larson, Joseph J.; Ellinghaus, David; Franke, Andre; Lazaridis, Konstantinos N.

In: Liver international : official journal of the International Association for the Study of the Liver, Vol. 31, No. 6, 07.2011, p. 785-791.

Research output: Contribution to journalArticle

Juran, Brian D. ; Atkinson, Elizabeth J. ; Schlicht, Erik M. ; Larson, Joseph J. ; Ellinghaus, David ; Franke, Andre ; Lazaridis, Konstantinos N. / Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis. In: Liver international : official journal of the International Association for the Study of the Liver. 2011 ; Vol. 31, No. 6. pp. 785-791.
@article{e20dd2b7e09946e3ae2ebacb00583bd9,
title = "Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis.",
abstract = "The damaging cholestasis inherent to primary sclerosing cholangitis (PSC) results from bile duct stricturing because of progressive fibrosis. The matrix metalloproteinase 3 (MMP3) degrades a wide range of matrix components and is expressed by activated liver stellate cells, and so is a candidate for involvement with the fibrotic processes underlying PSC. Moreover, the MMP3 gene harbours polymorphisms associated with variation in its activity directly impacting clinical phenotypes. We aimed to examine the influence of MMP3 polymorphisms on PSC risk and progression. Nine single nucleotide polymorphisms (SNPs) tagging the common genetic variation of MMP3 were genotyped in 266 PSC patients and 407 controls. SNPs and inferred haplotypes were assessed for PSC association by logistic regression and score tests. The effect of SNPs on survival to liver transplant or death was analysed using Cox regression, and Kaplan-Meier curves were constructed. No association of PSC with individual SNPs or haplotypes of MMP3 was detected. However, progression to death or liver transplant was significantly associated with homozygosity for minor alleles of rs522616, rs650108 and rs683878, particularly among PSC patients with concurrent ulcerative colitis (UC) (strongest in redundant SNPs rs650108/rs683878, hazard ratio=3.23, 95{\%} confidence interval 1.45-7.25, P=0.004). Genetic variation in MMP3 influences PSC progression, possibly in the context of coexisting UC. While the functional variants and specific mechanisms remain unknown, this finding implicates the turnover of the extracellular matrix as an important and variable component of PSC pathogenesis. Efforts to understand this process could form the basis for developing effective treatments, which are currently lacking for PSC.",
author = "Juran, {Brian D.} and Atkinson, {Elizabeth J.} and Schlicht, {Erik M.} and Larson, {Joseph J.} and David Ellinghaus and Andre Franke and Lazaridis, {Konstantinos N.}",
year = "2011",
month = "7",
language = "English (US)",
volume = "31",
pages = "785--791",
journal = "Liver International",
issn = "1478-3223",
publisher = "Wiley-Blackwell",
number = "6",

}

TY - JOUR

T1 - Genetic polymorphisms of matrix metalloproteinase 3 in primary sclerosing cholangitis.

AU - Juran, Brian D.

AU - Atkinson, Elizabeth J.

AU - Schlicht, Erik M.

AU - Larson, Joseph J.

AU - Ellinghaus, David

AU - Franke, Andre

AU - Lazaridis, Konstantinos N.

PY - 2011/7

Y1 - 2011/7

N2 - The damaging cholestasis inherent to primary sclerosing cholangitis (PSC) results from bile duct stricturing because of progressive fibrosis. The matrix metalloproteinase 3 (MMP3) degrades a wide range of matrix components and is expressed by activated liver stellate cells, and so is a candidate for involvement with the fibrotic processes underlying PSC. Moreover, the MMP3 gene harbours polymorphisms associated with variation in its activity directly impacting clinical phenotypes. We aimed to examine the influence of MMP3 polymorphisms on PSC risk and progression. Nine single nucleotide polymorphisms (SNPs) tagging the common genetic variation of MMP3 were genotyped in 266 PSC patients and 407 controls. SNPs and inferred haplotypes were assessed for PSC association by logistic regression and score tests. The effect of SNPs on survival to liver transplant or death was analysed using Cox regression, and Kaplan-Meier curves were constructed. No association of PSC with individual SNPs or haplotypes of MMP3 was detected. However, progression to death or liver transplant was significantly associated with homozygosity for minor alleles of rs522616, rs650108 and rs683878, particularly among PSC patients with concurrent ulcerative colitis (UC) (strongest in redundant SNPs rs650108/rs683878, hazard ratio=3.23, 95% confidence interval 1.45-7.25, P=0.004). Genetic variation in MMP3 influences PSC progression, possibly in the context of coexisting UC. While the functional variants and specific mechanisms remain unknown, this finding implicates the turnover of the extracellular matrix as an important and variable component of PSC pathogenesis. Efforts to understand this process could form the basis for developing effective treatments, which are currently lacking for PSC.

AB - The damaging cholestasis inherent to primary sclerosing cholangitis (PSC) results from bile duct stricturing because of progressive fibrosis. The matrix metalloproteinase 3 (MMP3) degrades a wide range of matrix components and is expressed by activated liver stellate cells, and so is a candidate for involvement with the fibrotic processes underlying PSC. Moreover, the MMP3 gene harbours polymorphisms associated with variation in its activity directly impacting clinical phenotypes. We aimed to examine the influence of MMP3 polymorphisms on PSC risk and progression. Nine single nucleotide polymorphisms (SNPs) tagging the common genetic variation of MMP3 were genotyped in 266 PSC patients and 407 controls. SNPs and inferred haplotypes were assessed for PSC association by logistic regression and score tests. The effect of SNPs on survival to liver transplant or death was analysed using Cox regression, and Kaplan-Meier curves were constructed. No association of PSC with individual SNPs or haplotypes of MMP3 was detected. However, progression to death or liver transplant was significantly associated with homozygosity for minor alleles of rs522616, rs650108 and rs683878, particularly among PSC patients with concurrent ulcerative colitis (UC) (strongest in redundant SNPs rs650108/rs683878, hazard ratio=3.23, 95% confidence interval 1.45-7.25, P=0.004). Genetic variation in MMP3 influences PSC progression, possibly in the context of coexisting UC. While the functional variants and specific mechanisms remain unknown, this finding implicates the turnover of the extracellular matrix as an important and variable component of PSC pathogenesis. Efforts to understand this process could form the basis for developing effective treatments, which are currently lacking for PSC.

UR - http://www.scopus.com/inward/record.url?scp=80053483575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053483575&partnerID=8YFLogxK

M3 - Article

C2 - 21134112

VL - 31

SP - 785

EP - 791

JO - Liver International

JF - Liver International

SN - 1478-3223

IS - 6

ER -